X

Trial Profile

The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Somatropin (Primary)
Indications Growth disorders; Short stature; Somatotropin deficiency; Turner's syndrome
Focus Adverse reactions; Therapeutic Use
Acronyms GeNeSIS
Sponsors Eli Lilly and Company

Most Recent Events

20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
19 Apr 2017 New trial record
04 Apr 2017 Results (n=5076) analysing near adult height gains in Somatropin treated children with growth disorders from the GeNeSIS observational study, presented at The 99th Annual Meeting of the Endocrine Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com